Article citationsMore>>
N. Bijker, J. L. Peterse, L. Duchateau, J. P. Julien, I. S. Fentiman, C. Duval, S. Di Palma, J. Simony-Lafontaine, I. de Mascarel and M. J. van de Vijver, “Risk Factors for Recurrence and Metastasis after Breast Conserving Therapy for Ductal Carcinoma in-Situ: Analysis of European Organisation for Research and Treatment of Cancer Trial 10853,” Journal of Clinical Oncology, Vol. 19, No. 8, 2001, pp. 2263-2271.
has been cited by the following article:
-
TITLE:
Current Treatment of DCIS
AUTHORS:
Christina Choy, Kefah Mokbel
KEYWORDS:
Early Breast Cancer; DCIS; Breast Cancer Diagnosis and Treatment
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.2,
February
12,
2014
ABSTRACT:
Abstract: Ductal
carcinoma in-situ DCIS is a
heterogeneous entity in breast neoplasm with unpredictable biological behavior.
This poses challenge in the management of DCIS. Various trials on DCIS have
shown good outcome with integral treatment of adequate surgery, radiotherapy
and hormonal therapy. Identification of subgroup of DCIS for radiotherapy and
hormonal therapy could improve recurrence rate, contralateral tumours incidence
and perhaps overall survival. Various risk score calculations could help to
direct radiotherapy and hormonal treatment verses surgery alone and to avoid
over treatment. Oncotype DX
assay could be a new way of risk calculation to direct types of DCIS treatment.
The recent increased use of MRI could increase the detection of DCIS and a more
accurate extent of disease estimation. This article is a summary of major
literatures and major trials result for DCIS.
Related Articles:
-
Casimir Komenan
-
Jai Dev Chandel, Nand Lal Singh
-
Ngozi Grace Emordi, Iweriolor Sunday, Onyekpe Basil Obimma
-
Giancarlo T. Tomezzoli
-
Anqi Ding, Ting Zhang